Advertisement
Document › Details
Ablynx N.V.. (11/9/17). "Press Release: Ablynx to Present at Upcoming Investor Conferences in London and Paris". Ghent.
Region | London, Greater London | |
Country | United Kingdom (GB) | |
Organisation | Ablynx N.V. (Euronext Brussels: ABLX, Nasdaq: ABLX) | |
Group | Sanofi (Group) [since May 2011] | |
Organisation 2 | Bryan, Garnier & Co., Ltd., Paris | |
Group | Bryan, Garnier (Group) | |
Product | Nanobodies® (Ablynx) | |
Index term | Ablynx–Leucadia: investor conference, 201711 supply service Ablynx presents at Annual Jefferies Healthcare Conference London | |
Index term 2 | Ablynx–Bryan Garnier: investor conference, 201711 supply service Ablynx participates at Bryan Garnier Annual Healthcare Conference in Paris | |
Person | Moses, Edwin (Ablynx 200603– CEO before non-exec Board Member 200411– before Oxford Asymmetry) | |
Person 2 | Elliott, Mary-Jane (Consilium SC 201307– Managing Partner + Co-founder before M:Communications) | |
Ablynx [Euronext Brussels and Nasdaq: ABLX] today announces that it will participate in the following upcoming investor conferences taking place in London, UK and Paris, France:
> Jefferies 2017 Healthcare Conference in London: a presentation is scheduled for Thursday 16 November 2017 at 02:00 p.m. GMT (03:00 p.m. Central European Time) together with one-onone meetings with institutional investors. The presentation, given by Dr Edwin Moses, CEO of Ablynx, will be webcast live and can be accessed on the day via this link. The presentation will be available on the Company’s website, under the News & Events section for 90 days following the event.
> Bryan, Garnier & Co Annual Healthcare Conference in Paris: one-on-one meetings with institutional investors are scheduled for Friday 17 November 2017.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact:
Ablynx
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Lies Vanneste
Director IR
t: +32 (0)9 262 0137
m: +32 (0)498 05 35 79
e: lies.vanneste@ablynx.com
@AblynxABLX
Ablynx media relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700
e: ablynx@consilium-comms.com
Disclaimer
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forwardlooking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its parent or subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Record changed: 2023-06-05 |
Advertisement
More documents for Sanofi (Group) [since May 2011]
- [1] GenSight Biologics S.A.. (12/22/23). "Press Release: GenSight Biologics Appoints Laurence Rodriguez as Chief Executive Officer". Paris....
- [2] Sanofi S.A.. (12/11/23). "Press Release: Statement on FTC Challenge to Proposed License Agreement with Maze Therapeutics". Paris....
- [3] Eligo Bioscience S.A.. (12/5/23). "Press Release: Eligo Bioscience Raises $30 Million To Write a Novel Chapter for Genetic Medicines". Paris....
- [4] Aqemia S.A.S.. (12/5/23). "Press Release: Aqemia Announces a Major Multi-year Collaboration of $140 Million with Sanofi". Paris....
- [5] MeiraGTx Holdings plc. (10/30/23). "Press Release: MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities". London & New York, NY....
- [6] Sanofi S.A.. (10/3/23). "Press Release: Sanofi Announces Agreement for Potential First-in-Class Vaccine against Extraintestinal Pathogenic E. coli". Paris....
- [7] Sanofi S.A.. (3/13/23). "Press Release: Sanofi to Acquire Provention Bio, Adding to Portfolio TZIELD, the First Disease-modifying Treatment for the Delay of Stage 3 Type 1 Diabetes (T1D)". Paris & Red Bank, NJ....
- [8] Avilar Therapeutics, Inc.. (2/16/23). "Press Release: Avilar Therapeutics Increases Financing to $75 Million to Advance Pipeline of Novel Extracellular Protein Degraders". Waltham, MA....
- [9] Sanofi S.A.. (1/11/23). "Press Release: Sanofi Ventures Announces Multi-year Capital Commitment from Sanofi, Increasing Evergreen Fund to $750M". Paris....
- [10] CureVac N.V.. (1/10/23). "Press Release: CureVac Appoints Alexander Zehnder as CEO from April 1, 2023". Mainz & London....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top